Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters

Database
Language
Affiliation country
Publication year range
1.
Int J Mol Sci ; 22(21)2021 Oct 27.
Article in English | MEDLINE | ID: mdl-34769059

ABSTRACT

Methionine restriction (MetR) is an efficient method of amino acid restriction (AR) in cells and organisms that induces low energy metabolism (LEM) similar to caloric restriction (CR). The implementation of MetR as a therapy for cancer or other diseases is not simple since the elimination of a single amino acid in the diet is difficult. However, the in vivo turnover rate of cysteine is usually higher than the rate of intake through food. For this reason, every cell can enzymatically synthesize cysteine from methionine, which enables the use of specific enzymatic inhibitors. In this work, we analysed the potential of cysteine restriction (CysR) in the murine cell line L929. This study determined metabolic fingerprints using mass spectrometry (LC/MS). The profiles were compared with profiles created in an earlier work under MetR. The study was supplemented by proliferation studies using D-amino acid analogues and inhibitors of intracellular cysteine synthesis. CysR showed a proliferation inhibition potential comparable to that of MetR. However, the metabolic footprints differed significantly and showed that CysR does not induce classic LEM at the metabolic level. Nevertheless, CysR offers great potential as an alternative for decisive interventions in general and tumour metabolism at the metabolic level.


Subject(s)
Cysteine/metabolism , Fibroblasts/metabolism , Methionine/metabolism , Neoplasms/metabolism , Animals , Caloric Restriction/methods , Cell Line , Diet/methods , Mice
2.
EMBO J ; 37(22)2018 11 15.
Article in English | MEDLINE | ID: mdl-30389661

ABSTRACT

Nutrient overload in combination with decreased energy dissipation promotes obesity and diabetes. Obesity results in a hormonal imbalance, which among others activates G protein-coupled receptors utilizing diacylglycerol (DAG) as secondary messenger. Protein kinase D1 (PKD1) is a DAG effector, which integrates multiple nutritional and hormonal inputs, but its physiological role in adipocytes is unknown. Here, we show that PKD1 promotes lipogenesis and suppresses mitochondrial fragmentation, biogenesis, respiration, and energy dissipation in an AMP-activated protein kinase (AMPK)-dependent manner. Moreover, mice lacking PKD1 in adipocytes are resistant to diet-induced obesity due to elevated energy expenditure. Beiging of adipocytes promotes energy expenditure and counteracts obesity. Consistently, deletion of PKD1 promotes expression of the ß3-adrenergic receptor (ADRB3) in a CCAAT/enhancer binding protein (C/EBP)-α- and δ-dependent manner, which leads to the elevated expression of beige markers in adipocytes and subcutaneous adipose tissue. Finally, deletion of PKD1 in adipocytes improves insulin sensitivity and ameliorates liver steatosis. Thus, depletion of PKD1 in adipocytes increases energy dissipation by several complementary mechanisms and might represent an attractive strategy to treat obesity and its related complications.


Subject(s)
Adipocytes/metabolism , Adiposity , Energy Metabolism , Fatty Liver/metabolism , Obesity/metabolism , Protein Kinase C/metabolism , Subcutaneous Fat/metabolism , 3T3-L1 Cells , Adipocytes/pathology , Animals , CCAAT-Enhancer-Binding Protein-delta/genetics , CCAAT-Enhancer-Binding Protein-delta/metabolism , CCAAT-Enhancer-Binding Proteins/genetics , CCAAT-Enhancer-Binding Proteins/metabolism , Fatty Liver/genetics , Fatty Liver/pathology , Female , Humans , Male , Mice , Mice, Mutant Strains , Obesity/genetics , Obesity/pathology , Protein Kinase C/genetics , Receptors, Adrenergic, beta-3/genetics , Receptors, Adrenergic, beta-3/metabolism , Second Messenger Systems/genetics , Subcutaneous Fat/physiology
3.
Chemosphere ; 72(3): 517-23, 2008 Jun.
Article in English | MEDLINE | ID: mdl-18410951

ABSTRACT

Biomineralization dependent on bacterial activity has been described for struvite which is formed in soils, guano, putrescent matter and sediments. A new biomineral containing nickel instead of magnesium, Ni(NH4)(PO4) . 6H2O, has been identified. It was formed by nickel resistant Streptomyces acidiscabies E13, and putatively named nickel struvite. The mineral formation is dependent on biological activity since non-viable bacterial cells are not capable to induce formation of Ni-struvite under identical conditions. Formation of Ni-struvite was observed on colony surfaces upon prolonged incubation of solid minimal or complex media containing elevated concentrations of 8-15mM NiCl2. The formation of magnesium containing crystals was not observed although Mg2+ is present in the medium. However, the process was not depending on desiccation since small crystals attached to the mycelial biomass of the bacteria were observed microscopically also in liquid cultures of nickel supplemented minimal and complex media after two weeks of incubation. The capacity to induce biomineralization of a nickel containing mineral is postulated to constitute a resistance factor, allowing the soil bacterium to withstand high nickel concentrations. The strain shows nickel resistance as an adaption to its habitat, since this bacterium was isolated from a former uranium mining site in Eastern Thuringia, Germany, where nickel concentrations of up to 2000ppm (translating to appr. 30mM) occur as a result of former mining activities.


Subject(s)
Magnesium Compounds/metabolism , Nickel/metabolism , Phosphates/metabolism , Streptomyces/metabolism , Crystallization , Dose-Response Relationship, Drug , Drug Resistance, Bacterial , Electron Probe Microanalysis , Magnesium Compounds/chemistry , Nickel/chemistry , Nickel/toxicity , Phosphates/chemistry , Soil Pollutants/chemistry , Soil Pollutants/metabolism , Soil Pollutants/toxicity , Streptomyces/drug effects , Struvite , X-Ray Diffraction
4.
Hum Mol Genet ; 13(9): 955-65, 2004 May 01.
Article in English | MEDLINE | ID: mdl-15016763

ABSTRACT

alpha-Methylacyl-CoA racemase (Amacr) deficiency in humans leads to sensory motor neuronal and liver abnormalities. The disorder is recessively inherited and caused by mutations in the AMACR gene, which encodes Amacr, an enzyme presumed to be essential for bile acid synthesis and to participate in the degradation of methyl-branched fatty acids. To generate a model to study the pathophysiology in Amacr deficiency we inactivated the mouse Amacr gene. As per human Amacr deficiency, the Amacr(-/-) mice showed accumulation (44-fold) of C27 bile acid precursors and decreased (over 50%) primary (C24) bile acids in bile, serum and liver, however the Amacr(-/-) mice were clinically symptomless. Real-time quantitative PCR analysis showed that, among other responses, the level of mRNA for peroxisomal multifunctional enzyme type 1 (pMFE-1) was increased 3-fold in Amacr(-/-) mice. This enzyme can be placed, together with CYP3A11 and CYP46A1, to make an Amacr-independent pathway for the generation of C24 bile acids. Exposure of Amacr(-/-) mice to a diet supplemented with phytol, a source for branched-chain fatty acids, triggered the development of a disease state with liver manifestations, redefining the physiological significance of Amacr. Amacr is indispensable for the detoxification of dietary methyl-branched lipids and, although it contributes normally to bile acid synthesis from cholesterol, the putative pMFE-1-mediated cholesterol degradation can provide for generation of bile acids, allowing survival without Amacr. Based upon our mouse model, we propose elimination of phytol from the diet of patients suffering from Amacr deficiency.


Subject(s)
Bile Acids and Salts/biosynthesis , Deficiency Diseases/etiology , Lipids/pharmacology , Racemases and Epimerases/deficiency , Animals , Aryl Hydrocarbon Hydroxylases/genetics , Aryl Hydrocarbon Hydroxylases/metabolism , Bile Acids and Salts/metabolism , Body Weight/genetics , Cholesterol/blood , Cholesterol/metabolism , Cholesterol 24-Hydroxylase , Clofibrate/pharmacology , Cytochrome P-450 CYP3A , Deficiency Diseases/drug therapy , Deoxyribonucleases, Type II Site-Specific/genetics , Dietary Fats/pharmacology , Disease Models, Animal , Female , Gene Expression Regulation , Hypolipidemic Agents/pharmacology , Kidney/enzymology , Lipids/blood , Lipids/chemistry , Liver/enzymology , Liver/pathology , Male , Membrane Proteins , Mice , Mice, Mutant Strains , Oxidoreductases, N-Demethylating/genetics , Oxidoreductases, N-Demethylating/metabolism , Phytol/pharmacology , Racemases and Epimerases/genetics , Racemases and Epimerases/metabolism , Steroid Hydroxylases/genetics , Steroid Hydroxylases/metabolism , Vitamin K/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL